Citing significant progress on a cure for diabetes, Novo Nordisk beefs up its stem cell pipeline with new collaborations
A growing group of biotech startups looking to advance a lineup of potential stem cell cures for Type 1 diabetes can look to a big and very effective rival moving forward in the field.
Novo Nordisk says it’s been making major progress on developing the embryonic stem cell lines it needs for a world-class manufacturing operation. And Novo adds that they’ve also been moving forward in developing a new encapsulation device to guard their stem cell therapy from a destructive immune response — all part of the Holy Grail for developing a cure for the disease.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.